Navigation Links
Yuma Therapeutics Awarded a Research Grant by the Alzheimer's Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimer's Disease
Date:3/28/2011

NEW YORK, March 28, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer's disease.

(Logo: https://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The award will fund work to develop Yuma's innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer's disease.

"We are excited to support Yuma Therapeutics innovative program in this area," said Howard Fillit, M.D., executive director of the ADDF.  "Small molecule therapeutics targeting the tau pathway could result in a disease-modifying therapy for Alzheimer's disease."

"We are honored to be selected for this peer-reviewed grant, which recognizes the promise of Yuma's approach to generating novel Alzheimer's disease therapies," said Yukari Y. Perrella, founder and president of Yuma.  "We look forward to interacting with the ADDF team."

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries. 

About Yuma Therapeutics Corporation (www.yumatherapeutics.com)

Yuma Therapeutics is a privately held biopharmaceutical company focused on developing novel disease-modifying small molecule drugs to treat neurodegenerative diseases.  The Company is developing pharmaceutical compounds that target the tau pathway, a promising new approach to affect the disease progression of Alzheimer's disease.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
2. Reportlinker Adds Therapeutics for Immune System Disorders
3. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
4. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
5. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
6. Echo Therapeutics Announces 2010 Financial Results
7. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
8. Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
11. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...   Genomic Health, Inc. (Nasdaq: GHDX ) today ... ended December 31, 2015. --> --> ... compared with $69.1 million in the fourth quarter of 2014, an ... 9 percent compared with the same period in the prior year. ... $63.9 million in the fourth quarter of 2015, an increase of ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
Breaking Medicine Technology:
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... Washington (PRWEB) , ... February 10, 2016 , ... ... access and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart ... remote interpreting (VRI). , For nearly 23 years, Heart City Health Center has ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Valley , announces that his office is now offering a variety of comprehensive ... enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. ...
Breaking Medicine News(10 mins):